Rhinosinusitis
Drug research and approvals for rhinosinusitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 67 studies of rhinosinusitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 24 drug trials for it since 2013, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 67
- Trials authorized in Canada: 24
- FDA orphan approvals: 0
- EU medicines: 1
- Olfactory Function in Patients With Sinonasal Diseases: A Multicenter Observational StudyNCT07942571 · Not reported · University of Brasilia · starts Mar 1, 2025
- Metabolic and Immunologic Biomarkers in Chronic Rhinosinusitis With Nasal PolypsNCT07860411 · Not reported · Harran University · starts Mar 15, 2026
- Mepolizumab and in Office-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS).NCT07814924 · Phase 4 · Instituto de Investigación Marqués de Valdecilla · starts Dec 31, 2024
- A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis…NCT07782970 · Phase 3 · GlaxoSmithKline · starts Sep 28, 2026
- A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With…NCT07782957 · Phase 3 · GlaxoSmithKline · starts Sep 3, 2026
- Triamcinolone Nanocapsules After Endoscopic Nasal SurgeryNCT07714525 · Phase 2 · Deraya University · starts May 1, 2026
- Efficacy and Safety of Depemokimab Monotherapy Without Concomitant Use of Intranasal Corticosteroids (INCS) in Japanese…NCT07701967 · Phase 4 · GlaxoSmithKline · starts Jul 15, 2026
- Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT): Open LabelNCT07689773 · Phase 2 · Medical University of South Carolina · starts Jul 10, 2026
- Cognitive and Immunologic Profiles of Patients With Olfactory Dysfunction After Smell TrainingNCT07681973 · Not applicable · The Cleveland Clinic · starts Dec 9, 2025
How its trials ended
378 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 76 whose ending is known, 36% met their primary endpoint, 5% missed it and 59% stopped early.
- Completed, result not reported14939%
- Ongoing10327%
- Status unknown5013%
- Met its primary endpoint277%
- Stopped: other or unclear267%
- Stopped: enrollment or feasibility113%
- Stopped: lack of efficacy51%
- Missed its primary endpoint41%
- Stopped: funding21%
- Stopped: sponsor or business decision1<1%
| Feb 24, 2026 | A double-blinded extension study to evaluate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chronic…Itepekimab (SAR440340) | Sanofi-Aventis Canada Inc | Closed |
| Oct 9, 2025 | The efficacy of intra-sinus povidone-iodine/budesonide gel forming suspension following endoscopic sinus surgery for chronic rhinosinusitis: a randomized,…Povidone iodine-budesonide | St Pauls Hospital Vancouver | Ongoing |
| Dec 31, 2024 | Determining the immunologic impact of dupilumab on the unified airway system in patients suffering from asthma and chronic rhinosinusitis with polypsDupixent | St Paul's Sinus Centre | Pending |
| Dec 5, 2024 | A randomized, double-blind, placebo-controlled, parallel-group, 52-week phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in…SAR440340 (itepekimab) | Sanofi-Aventis Canada Inc | Ongoing |
| Dec 5, 2024 | A randomized, double-blind, placebo-controlled, parallel-group, 52-week phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in…SAR440340 (itepekimab) | Sanofi-Aventis Canada Inc | Closed |
| Oct 29, 2024 | Opening the 'black box' on tezepelumab's effect of chronic rhinosinusitis with severe asthmaTezspire | St Paul's Sinus Centre | Ongoing |
| Oct 4, 2024 | A randomized, double-blind, placebo-controlled, proof-of-concept (POC) study to assess the efficacy, safety, and tolerability of itepekimab in participants…Itepekimab (SAR440340) | Sanofi-Aventis Canada Inc | Closed |
| Apr 25, 2024 | A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of lebrikizumab/LY3650150 in…Lebrikizumab (LY3650150) | Eli Lilly | Ongoing |
| Aug 10, 2023 | Multicenter, randomized, double-blinded, placebo-controlled, phase 2 clinical efficacy study evaluating nitric oxide nasal spray (NONS) compared to saline…Nitric oxide | Sanotize Research & Development Corp | Ongoing |
| Aug 4, 2023 | A phase 2b, randomized, double-blind, placebo-controlled, multicenter study of the efficacy and safety of brensocatib in participants with chronic…Brensocatib (INS1007) | Insmed | Closed |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Dec 1, 2015 | NucalaMepolizumab | GlaxoSmithKline Trading Services Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA